



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/846,863	05/01/2001	Philip Goelet	13020-2-D1	5388

7590 06/02/2004  
Kalow & Springut LLP  
488 Madison Avenue, 19th Floor  
New York, NY 10022

EXAMINER

SISSON, BRADLEY L

ART UNIT PAPER NUMBER

1634

DATE MAILED: 06/02/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

3M-  
**Office Action Summary**

Application No.

09/846,863

Applicant(s)

GOELET ET AL.

Examiner

Bradley L. Sisson

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 16 January 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 32-55 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 32-55 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Oath/Declaration***

1. In light of the amendment to the claims, the requirement for a supplemental oath or declaration has been withdrawn.

### ***Specification***

2. The disclosure is objected to because of the following informalities:
3. The newly amended paragraph found at page 1, line 18, of the specification lists various US Patent applications but does not reflect the current status of same. It is noted with particularity that U.S. Patent Application Serial Nos. 08/971,344, 08/216538, and 08/145,145 are all abandoned. While the specification does indicate that the '145 application has been abandoned, such indication for the '344 and the '538 application is missing.
4. Similarly, the specification at page 25, line 7; page 34, line 5; and page 51, line 17, refers to US Patent Application Serial No. 08/005,061, however, the current status of the referenced application (abandoned) is not provided.

Appropriate correction is required.

5. The specification is objected to as documents have been improperly incorporated by reference. In particular, the specification states at page 25, lines 29-30, that "all [documents are] herein incorporated by reference." Similar language is also found at page 25, lines 7-8; page 13, lines 10-11; page 23, line 32; page 24, line 3. Such omnibus language fails to specify what

Art Unit: 1634

specific information applicant seeks to incorporate by reference and similarly fails to teach with detailed particularity just where that specific information is to be found in each of the cited documents. As set forth in *Advanced Display Systems Inc. v. Kent State University* (Fed. Cir. 2000) 54 USPQ2d at 1679:

Incorporation by reference provides a method for integrating material from various documents into a host document--a patent or printed publication in an anticipation determination--by citing such material in a manner that makes it clear that the material is effectively part of the host document as if it were explicitly contained therein. *See General Elec. Co. v. Brenner*, 407 F.2d 1258, 1261-62, 159 USPQ 335, 337 (D.C. Cir. 1968); *In re Lund*, 376 F.2d 982, 989, 153 USPQ 625, 631 (CCPA 1967). **To incorporate material by reference, the host document must identify with detailed particularity what specific material it incorporates and clearly indicate where that material is found in the various documents.** *See In re Seversky*, 474 F.2d 671, 674, 177 USPQ 144, 146 (CCPA 1973) (providing that incorporation by reference requires a statement "clearly identifying the subject matter which is incorporated and where it is to be found"); *In re Saunders*, 444 F.2d 599, 602-02, 170 USPQ 213, 216-17 (CPA 1971) (reasoning that a rejection or anticipation is appropriate only if one reference "expressly incorporates a particular part" of another reference); *National Latex Prods. Co. v. Sun Rubber Co.*, 274 F.2d 224, 230, 123 USPQ 279, 283 (6<sup>th</sup> Cir. 1959) (requiring a specific reference to material in an earlier application in order to have that material considered a part of a later application); *cf. Lund*, 376 F.2d at 989, 13 USPQ at 631 (holding that **a one sentence reference to an abandoned application is not sufficient to incorporate from the abandoned application into a new application**). (Emphasis added.)

Accordingly, the cited documents are not considered to have been properly incorporated by reference and as such, have not been considered with any effect towards their fulfilling, either in part or in whole, the enablement, written description, or best mode requirements of 35 USC 112, first paragraph.

### ***Claim Rejections - 35 USC § 112***

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it

Art Unit: 1634

pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 32-5 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

8. Attention is directed to the decision in *University of Rochester v. G.D. Searle & Co.* 68 USPQ2D 1424 (Fed. Cir. 2004) at 1428:

To satisfy the written-description requirement, the specification must describe every element of the claimed invention in sufficient detail so that one of ordinary skill in the art would recognize that the inventor possessed the claimed invention at the time of filing. *Vas-Cath*, 935 F.3d at 1563; see also *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572 [41 USPQ2d 1961] (Fed. Cir. 1997) (patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that “the inventor invented the claimed invention”); *In re Gosteli*, 872 F.2d 1008, 1012 [10 USPQ2d 1614] (Fed. Cir. 1989) (“the description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed”). Thus, an applicant complies with the written-description requirement “by describing the invention, with all its claimed limitations, not that which makes it obvious,” and by using “such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention.” *Lockwood*, 107 F.3d at 1572.

For convenience, claims 32 and 39, the only independent claims, are reproduced below.

Claim 32 (currently amended): A method for identifying single nucleotide polymorphic sites in a genome of a species of interest, comprising:

- (a) isolating a plurality of DNA fragments from the genome of a population of individual representatives of the species of interest, wherein each fragment corresponds to a location of the genome and the fragments are between about 0.1 kb and 10.0 kb;
- (b) sequencing the DNA fragments to determine the nucleotide sequences of each fragment, and
- (c) comparing the sequence of each fragment to corresponding fragments from other individual representatives of the species of interest to identify sites of sequence variation, wherein the species of interest is a mammal.

Claim 39 (currently amended): A method for determining allelic frequency at a single nucleotide polymorphic site, comprising:

- (a) isolating a plurality of DNA fragments from a population of two or more individual representatives of a species of interest, wherein each fragment corresponds to a location of the genome and the fragments are between about 0.1 kb and 10.0 kb;
- (b) sequencing the DNA fragments to determine the nucleotide sequences of each fragment;
- (c) comparing the sequence of each fragment to corresponding DNA fragments from different individual representatives of the species of interest and identifying single nucleotide polymorphic sites having at least two alleles,
- (d) determining the base identity of each allele present in the location of the genome, and
- (e) calculating the allelic frequency for each allele by dividing the frequency at which each allele appears in the sample set by the total number of individuals, wherein the species of interest is a mammal.

9. As presently worded, the method of claim 32 has been interpreted as encompassing the identification of an infinite number of single nucleotide polymorphisms in any and all regions of a genome of any mammal. Said method has also been interpreted as fairly encompassing the simultaneous detection and identification of any and all single nucleotide polymorphisms in any and all DNA fragments, where the DNA fragments represent the same, complete, or different

Art Unit: 1634

segments of genomes of different subspecies and/or variants of any and all mammals. Said claims have also been interpreted as encompassing performing said determination when there does not exist any knowledge of any part of the nucleotide sequence of any or all of the fragments.

10. A review of the disclosure finds the following examples:

Page 45:

**EXAMPLE 1**  
**DISCOVERY OF EQUINE POLYMORPHISMS**

Page 47:

**EXAMPLE 2**  
**CHARACTERIZATION OF EQUINE POLYMORPHISMS**

Page 50:

**EXAMPLE 3**  
**ALLELIC FREQUENCY ANALYSIS OF EQUINE POLYMORPHISMS IN SMALL  
POPULATION STUDIES**

Page 55:

**EXAMPLE 4**  
**PARENTAGE TESTING**

Art Unit: 1634

Page 56:

**EXAMPLE 5**  
**IDENTITY TESTING**

Page 58:

**EXAMPLE 6**  
**ANALYSIS OF A HUMAN SNP**

11. Of the six examples provided, none disclose how one would test and evaluate the myriad “species of interest,” much less identify said single nucleotide polymorphisms in a simultaneous manner any number of individuals (claims 32, 36-39, and 43-45), or when testing the “smaller” value of 10,000 individuals (limitation of claims 35 and 42).

12. While the specification does present several examples, such are directed to the analysis of but equine and human DNA and then primarily to the analysis of equine DNA as it relates to parentage analysis (Example 4). Said six examples do not provide an adequate written description of the claimed method whereby one would be able to determine any and all single nucleotide polymorphisms in any and all species of mammals. As presently worded, the claimed method fairly encompasses performing the identification when but one strand is sequenced and/or is present in but only one haploid example. Page 47 of the disclosure, however, teaches, “Differences were concluded to be a DNA polymorphism only if the data was available for both strands, and/or present in more than one haploid example among the five horses tested.” The specification does not provide an adequate written description of how to practice the full scope



of the invention where but one strand is analyzed and/or where the frequency of the polymorphism is less frequent than 1 in 5, be the species human, equine, or otherwise.

13. Clearly, the limited disclosure provided by the specification does not constitute an adequate written description of the full genus of embodiments encompassed by the claims. Such limited disclosure also does not reasonably suggest that applicant was in possession of the claimed invention at the time of filing. Accordingly, and in the absence of convincing evidence to the contrary, Claims 32-55 are rejected under 35 USC 112, first paragraph, as failing to comply with the written description requirement.

14. Claims 32-55 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. As set forth in *Enzo Biochem Inc., v. Calgene, Inc.* (CAFC, 1999) 52 USPQ2d at 1135, bridging to 1136:

To be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without 'undue experimentation.' " *Genentech, Inc. v. Novo Nordisk, A/S*, 108 F.3d 1361, 1365, 42 USPQ2d 1001, 1004 (Fed. Cir. 1997) (quoting *In re Wright*, 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)). Whether claims are sufficiently enabled by a disclosure in a specification is determined as of the date that the patent application was first filed, see *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1384, 231 USPQ 81, 94 (Fed. Cir. 1986).... We have held that a patent specification complies with the statute even if a "reasonable" amount of routine experimentation is required in order to practice a claimed invention, but that such experimentation must not be "undue." See, e.g., *Wands*, 858 F.2d at 736-37, 8 USPQ2d at 1404 ("Enablement is not precluded by the necessity for some experimentation . . . However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue,' not 'experimentation.' ") (footnotes, citations, and internal quotation marks omitted). In *In re Wands*, we set forth a number of factors which a court may consider in determining whether a disclosure would require undue experimentation. These factors were set forth

Art Unit: 1634

as follows: (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims. *Id.* at 737, 8 USPQ2d at 1404. We have also noted that all of the factors need not be reviewed when determining whether a disclosure is enabling. See *Amgen, Inc. v. Chugai Pharm. Co., Ltd.*, 927 F.2d 1200, 1213, 18 USPQ2d 1016, 1027 (Fed. Cir. 1991) (noting that the *Wands* factors "are illustrative, not mandatory. What is relevant depends on the facts.>").

15. Of the six examples provided, none disclose how one would test and evaluate the myriad "species of interest," much less identify said single nucleotide polymorphisms in a simultaneous manner any number of individuals (claims 32, 36-39, and 43-45), or when testing the "smaller" value of 10,000 individuals (limitation of claims 35 and 42).

16. While the specification does present several examples, such are directed to the analysis of but equine and human DNA and then primarily to the analysis of equine DNA as it relates to parentage analysis (Example 4). Said six examples do not enable the identification of mutations in any and all mammalian species of interest.

17. As presently worded, the method of claims 32-47 fairly encompasses the analysis of virtually any mammal. And in the case of claims 32 and 40, virtually an infinite number of individuals can be tested simultaneously and that the reaction comprises DNA fragments from the entire genome of an infinite number of individuals from an infinite number of species of mammals. The six examples provided do not set forth a reproducible procedure whereby one of skill in the art would be able to correctly associate a potential polymorphism with a given sequence when similar sequences are present yet belong to a different species of mammal. Assuming *arguendo* that one of skill in the art would have been able to identify SNPs in any genetic materials found in any "species of interest," a position that the Office does not concede,

Art Unit: 1634

such is not enough to enable the claimed method in that the specification must also enable the use of the SNPs. As shown above, the claims method is considered to encompass the identification of SNPs in any "species of interest" where said species of interest encompasses all life forms as well as all viruses. The method clearly encompassing mutations that are silent as well as non-silent, yet the specification is effectively silent as to how one is to use such mutations in any mammalian species of interest.

18. In view of the breadth of scope of the claims, the introduction of new matter into the disclosure, the limited disclosure provided, the unpredictability in the art, claims 32-45 are not enabled by the disclosure. Accordingly, and in the absence of convincing evidence to the contrary, claims 32-45 are rejected under 35 USC, 112, first paragraph, as not being enabled by the disclosure.

Response to argument

19. At page 8, bridging to page 9 of the response received 16 January 2004, applicant asserts that the claimed method satisfies both the enablement and written description requirements of 35 USC 112, first paragraph. Applicant asserts in part:

While the illustrative examples in the specification are directed to horse and human studies, one of ordinary skill in the art upon reading the specification would readily understand that the methods and use of SNPs would be applicable to all species including mammals. Applicants have described this applicability throughout their specification. Therefore, it is respectfully submitted that the specification teaches and fully enables methods for identifying single nucleotide polymorphic sites in the genome of mammals.

The above argument has been fully considered and has not been found persuasive towards the withdrawal of the rejection as it relates to both enablement and written description requirements. It appears that applicant is attempting to satisfy the written description requirement of 35 USC 112, first paragraph, through obviousness in that a skilled artisan is to somehow extrapolate from

Art Unit: 1634

the limited guidance of horses and humans to any and all mammals, including, but not limited to tamarinds, kangaroos, dolphins, whales, bats, rhinos, etc. Obviousness, however, cannot be relied upon for satisfaction of the written description requirement. In support of this position, attention is directed to the decision in *University of California v. Eli Lilly and Co.* (Fed. Cir. 1997) 43 USPQ2d at 1405, citing *Lockwood v. American Airlines Inc.* (Fed. Cir. 1997) 41 USPQ2d at 1966:

Recently, we held that a description which renders obvious a claimed invention is not sufficient to satisfy the written description requirement of that invention.

20. While applicant has presented claims 50-55 that are limited to humans and horses, the specification still does not satisfy the written description requirements when, as noted above for claims 32 and 39, there can be present an infinite number of nucleic acid sequences, and that they can be from an infinite number of different individuals, and that the DNA fragments can be representative of the entire genome of some or all of the infinite number of individuals. The specification also does not satisfy the written description requirements in so far as adequately describing how one of skill in the art would be able to recognize those polymorphic sites that are useful and can be used in a method such as those of claims 46 and 47 where the individual is identified or the parentage of an individual is identified.

In order to practice the method of claims 46, 47, 49, and 50, one must first have identified the polymorphic sites. Or to put it another way, knowledge of useful and informative polymorphic sites in a given individual are essential starting materials. Absent these essential starting materials, one cannot practice the claimed method. The specification has not set forth a reproducible procedure whereby any human's identity and/or parentage can be identified. Similarly, the specification has not set forth the essential starting materials that would enable the

Art Unit: 1634

identification of self and parentage of any and all equine. The situation at hand is analogous to that in *Genentech v. Novo Nordisk A/S* 42 USPQ2d 1001. As set forth in the decision of the Court:

“ ‘[T]o be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation.’ *In re Wright* 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); *see also Amgen Inc. v. Chugai Pharms. Co.*, 927 F. 2d 1200, 1212, 18 USPQ2d 1016, 1026 (Fed Cir. 1991); *In re Fisher*, 427 F. 2d 833, 166 USPQ 18, 24 (CCPA 1970) (‘[T]he scope of the claims must bear a reasonable correlation to the scope of enablement provided by the specification to persons of ordinary skill in the art.’).

\*\*\*\*\*

“Patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable. *See Brenner v. Manson*, 383 U.S. 519, 536, 148 USPQ 689, 696 (1966) (starting, in context of the utility requirement, that ‘a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.’) Tossing out the mere germ of an idea does not constitute enabling disclosure. While every aspect of a generic claim certainly need not have been carried out by an inventor, or exemplified in the specification, reasonable detail must be provided in order to enable members of the public to understand and carry out the invention.

“It is true . . . that a specification need not disclose what is well known in the art. *See, e.g., Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1385, 231 USPQ 81, 94 (Fed. Cir. 1986). However, that general, oft-repeated statement is merely a rule of supplementation, not a substitute for a basic enabling disclosure. It means that the omission of minor details does not cause a specification to fail to meet the enablement requirement. However, when there is no disclosure of any specific starting material or any of the conditions under which a process can be carried out, undue experimentation is required; there is a failure to meet the enablement requirement that cannot be rectified by asserting that all the disclosure related to the process is within the skill of the art. It is the specification, not the knowledge of one skill in the art, that must supply the novel aspects of an invention in order to constitute adequate enablement. This specification provides only a starting point, a direction for further research. (Emphasis added)

Accordingly, and in the absence of convincing evidence to the contrary, claims 32-55 are rejected under 35 USC 112, first paragraph, as failing both the enablement and written description requirements.

***Conclusion***

21. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

22. A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

23. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L. Sisson whose telephone number is (571) 272-0751. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.

24. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1634

25. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Bradley L. Sisson  
Primary Examiner  
Art Unit 1634

BLS  
26 May 2004